{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-22-000339","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.178819+00:00","generated_at":"2026-06-24T03:45:59.078880+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Globus Medical Q2 net sales $263.6M (+5% YoY); GAAP EPS $0.53, non-GAAP $0.56; Enabling Tech +41.7%","bullets":["Net sales $263.6M, +5.0% as-reported and +6.5% constant currency vs Q2 2021.","GAAP net income $54.6M (+31.4% YoY); diluted EPS $0.53 vs $0.40.","Non-GAAP diluted EPS $0.56; adjusted EBITDA $91.9M (34.9% of sales).","Enabling Technologies sales $29.4M (+41.7%) driven by robotics and Excelsius 3D.","Reaffirmed FY2022 guidance: net sales $1.025B, non-GAAP diluted EPS $2.10."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-22-000339","json":"https://secwatch.observer/filing/0001562762-22-000339.json","markdown":"https://secwatch.observer/filing/0001562762-22-000339.md","text":"https://secwatch.observer/filing/0001562762-22-000339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276222000339/0001562762-22-000339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276222000339/gmed-20220804x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:45:59.078880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}